Key result
Selective activation of α1-adrenergic receptors with cirazoline abolished electrical conduction within rat pulmonary veins by depolarizing the diastolic membrane potential from -73.9 mV to -45.1 mV.
Why the study?
Pulmonary veins are involved in paroxysmal atrial fibrillation pathophysiology, and in rats, left atrium and pulmonary vein cardiomyocytes react differently to alpha1-adrenergic receptor activation.
Absolute Event Rate: -45.1% vs -73.9%
p-value: p=<0.001
Selective activation of α1-adrenergic receptors abolishes electrical conduction within the pulmonary veins without affecting the left atrium, highlighting a potential novel pharmacological approach for paroxysmal atrial fibrillation.
Does not support clinical changes in AF management; leaves open α1-adrenergic PV mechanisms in humans.
Pulmonary veins (PV) are involved in the pathophysiology of paroxysmal atrial fibrillation. In the rat, left atrium (LA) and PV cardiomyocytes have different reactions to α1-adrenergic receptor activation. In freely beating atria-PV preparations, we found that electrical field potential (EFP) originated from the sino-atrial node propagated through the LA and the PV. The α1-adrenergic receptor agonist cirazoline induced a progressive loss of EFP conduction in the PV whereas it was maintained in the LA. This could be reproduced in preparations electrically paced at 5 Hz in LA. During pacing at 10 Hz in the PV where high firing rate ectopic foci can occur, cirazoline stopped EFP conduction from the PV to the LA, which allowed the sino-atrial node to resume its pace-making function. Loss of conduction in the PV was associated with depolarization of the diastolic membrane potential of PV cardiomyocytes. Adenosine, which reversed the cirazoline-induced depolarization of the diastolic membrane potential of PV cardiomyocytes, restored full over-shooting action potentials and EFP conduction in the PV. In conclusion, selective activation of α1-adrenergic receptors results in the abolition of electrical conduction within the PV. These results highlight a potentially novel pharmacological approach to treat paroxysmal atrial fibrillation by targeting directly the PV myocardium.
No takes yet. Share an insight, caveat, or question.
Bredeloux et al. (2020) studied Paroxysmal atrial fibrillation (experimental model). Cirazoline (α1-adrenergic receptor agonist) vs. Basal conditions was evaluated on Diastolic membrane potential (DMP) in pulmonary vein cardiomyocytes (p=<0.001). Selective activation of α1-adrenergic receptors with cirazoline abolished electrical conduction within rat pulmonary veins by depolarizing the diastolic membrane potential from -73.9 mV to -45.1 mV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: